Skip to main content
Clinical Trials/NL-OMON38378
NL-OMON38378
Recruiting
Not Applicable

The role of gut microbiota and chronic inflammation as drivers of cardiovascular disease - Nijmegen Biomedical Study - Non Invasive markers of Atherosclerosis 3 - NBS-NIMA3

niversitair Medisch Centrum Sint Radboud0 sites500 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
500
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • \- participant NIMA\-NBS 2 study
  • \- body mass index \> 27 kg/m2

Exclusion Criteria

  • \- Recent cardiovascular event (myocardial infarction, transient ischemic attack, stroke \< 3 months)
  • \- History of bariatric surgery or bowel resection
  • \- Inflammatory bowel disease
  • \- Coagulation defects
  • \- Thrombocytopenia (thrombocytes \< 100 x 10E9\)
  • \- Liver dysfunction (INR \> 1\.6\)
  • \- Renal dysfunction (estimated glomerular filtration rate \< 30 ml/min/1\.72m2\)
  • \- Use of oral or subcutaneous anti\-coagulant therapy
  • \- Use of thrombocyte aggregation inhibitors other than acetylsalicylic acid or carbasalate calcium
  • \- Claustrofobia

Outcomes

Primary Outcomes

Not specified

Similar Trials